EUCTR2012-000694-23-ES进行中（未招募）1 期
Estudio de fase III, aleatorizado, multicéntrico y abierto, del inhibidor de la tirosina-cinasa de Bruton (BTK) ibrutinib frente a ofatumumab en pacientes con leucemia linfocítica crónica/linfoma linfocítico pequeño recidivante o resistente a tratamiento.A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton?s Tyrosine Kinase (BTK) Inhibitor Ibrutinib versus Ofatumumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Pharmacyclics, Incorporated0 个研究点目标入组 350 人开始时间: 2012年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 350
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Men and women ? 18 years of age
- •2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- •3. Life expectancy of > 4 months from the 1st dose of study medication
- •4. Diagnosis of CLL/SLL that meets published diagnostic criteria (Hallek 2008): a) Monoclonal B-cells (either kappa or lambda light chain restricted) that are clonally co expressing at least one B-cell marker (CD19, CD20, or CD23) and CD5, b) The diagnosis of CLL requires a history of lymphocytosis with a B-lymphocyte count ?5,000/µl while SLL patients are characterized by the same criteria with a circulating B lymphocyte count <5,000/µl. Prolymphocytes may comprise no more than 55% of blood lymphocytes
- •5. Active disease meeting at least 1 of the following IWCLL 2008 criteria for requiring treatment: a) Evidence of progressive marrow failure as manifested by the development of, or worsening of, anemia (Hgb < 11 g/dL) and/or thrombocytopenia (platelets < 100,000/L), b) Massive, progressive, or symptomatic splenomegaly, c) Massive nodes, progressive, or symptomatic lymphadenopathy, d) Progressive lymphocytosis with an increase of > 50% over a 2-month period or a lymphocyte doubling time (LDT) of < 6 months. LDT may be obtained by linear regression extrapolation of absolute lymphocyte counts (ALC) obtained at intervals of 2 weeks over an observation period of 2 to 3 months. In patients with initial blood lymphocyte counts of < 30 X 109/L (30,000/?L), LDT should not be used as a single parameter to define indication for treatment. In addition, factors contributing to lymphocytosis or lymphadenopathy other than CLL should be excluded, e) Autoimmune anemia and/or thrombocytopenia that is poorly responsive to corticosteroids or other standard therapy, f) Constitutional symptoms, defined as one or more of the following disease-related symptoms or signs, i) Unintentional weight loss > 10% within the previous 6 months prior to Screening
- •ii) Significant fatigue; iii) Fevers higher than 100.5° F or 38 .0° C for 2 or more weeks prior to Screening without evidence of infection or iv) Night sweats for more than 1 month prior to Screening without evidence of infection
- •6. Must have received at least one prior therapy for CLL/SLL and not be appropriate for treatment or retreatment with purine analog based therapy, defined by at least one of the following criteria: a) Failure to respond (stable disease [SD] or disease progression on treatment), or a progression-free interval of less than 3 years from treatment with a purine analog based therapy and anti-CD20 containing chemoimmunotherapy regimen after at least two cycles, b) Age ? 70 years, or age ? 65 and the presence of co-morbidities (Cumulative Illness Rating Scale [CIRS] ? 6 or CrCl < 70 mL/min) that might place the patient at an unacceptable risk for treatment-related toxicity with purine analog based therapy, provided they have received >1 prior treatment including at least two cycles of an alkylating-agent based (or purine analog based) anti-CD20 antibody containing chemoimmunotherapy regimen. CIRS score can be determined utilizing a web-based tool.
- •c) History of purine analog-associated autoimmune anemia or autoimmune thrombocytopenia, d) FISH showing 17p del in ? 20% of cells (either at diagnosis or any time before study entry) either alone or in combination with other cytogenetic abnormalities, provided they have received at least one prior therapy
- •7. Measurable nodal disease by CT.
- •8. Meet the following labor
排除标准
- •Patients will be ineligible for this study if they meet any of the following criteria:
- •1. Known central nervous system (CNS) lymphoma or leukemia
- •2. Any history of Richter?s transformation or prolymphocytic leukemia
- •3. No documentation of cytogenetic and/or FISH results reflecting 17p del status in records prior to first dose of study drug
- •4. Uncontrolled Autoimmune Hemolytic Anemia (AIHA) or ideopathic thrombocytopenia purpura (ITP), such as those patients with a declining hemoglobin (Hgb) level or platelet count secondary to autoimmune destruction within the 4 weeks prior to first dose of study drug or the need for daily corticosteroids >20 mg daily
- •5. Prior exposure to ofatumumab or to ibrutinib
- •6. Previous randomization in a PCI-32765/ibrutinib study
- •7. Received any chemotherapy, external beam radiation therapy, anticancer antibodies, or investigational drug within 30 days prior to first dose of study drug
- •8. Corticosteroid use within 1 week prior to first dose of study drug, except as indicated for other medical conditions such as inhaled steroid for asthma, topical steroid use, or as premedication for administration of study drug or contrast. Patients requiring steroids at daily doses > 20 mg prednisone equivalent systemic exposure daily, or those who are administered steroids for leukemia control or white blood cell count lowering are excluded
- •9. Radio- or toxin-conjugated antibody therapy within 10 weeks prior to first dose of study drug
- •10. Prior autologous transplant within 6 months prior to first dose of study drug
- •11. Prior allogeneic stem cell transplant within 6 months prior to first dose of study drug
- •12. Major surgery within 4 weeks prior to first dose of study drug
- •13. History of prior malignancy, with the exception of the following:
- •a) Malignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to Screening and felt to be at low risk for recurrence by treating physician
- •b) Adequately treated non-melanomatous skin cancer or lentigo maligna melanoma without current evidence of disease
- •c) Adequately treated cervical carcinoma in situ without current evidence of disease
- •14. Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, any Class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification, or history of myocardial infarction within 6 months prior to first dose with study drug
- •15. Unable to swallow capsules or disease significantly affecting gastrointestinal function and/or inhibiting small intestine absorption such as; malabsorption syndrome, resection of the small bowel, or poorly controlled inflammatory bowel disease affecting the small intestine
- •16. Uncontrolled active systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
- •17. Known history of infection with human immunodeficiency virus (HIV)
- •18. Serologic status reflecting active hepatitis B or C infection. Patients with hepatitis B core antibody positive who are antigen negative will need to have a negative polymerase chain reaction (PCR) result prior to enrollment. Those who are hepatitis B antigen positive or PCR positive will be excluded
- •19. History of stroke or intracranial hemorrhage within 6 months prior to enrollment
- •20. Pregnant or lactating women
研究者
相似试验
进行中（未招募）
1 期
Estudio de fase III, de muchos centros, aleatorizado a dos dosis distintas de medicación sin que el médico ni el paciente sepa en cual está, para evaluar la eficacia y seguridad de pasireotida LAR (de larga duración) en pacientes con enfermedad de Cushing.Enfermedad de CushingMedDRA version: 14.0Level: LLTClassification code 10011651Term: Cushing's diseaseSystem Organ Class: 10014698 - Endocrine disordersEUCTR2009-011128-70-ESovartis Farmacéutica, S.A.162
进行中（未招募）
1 期
Estudio de fase III, multicéntrico, aleatorizado y doble ciego para evaluar la eficacia y seguridad de BIBF 1120 en combinación con carboplatino y paclitaxel comparado con placebo en combinación con carboplatino y paclitaxel en pacientes con cáncer de ovario avanzado.Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer - BIBF 1120 or placebo in combination with standard chemotherapy in advanced ovarian cancerCáncer de ovario avanzado, cáncer de trompas de Falopio o cáncer peritoneal primario Advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancerMedDRA version: 9.1Level: LLTClassification code 10033128Term: Ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10016180Term: Fallopian tube cancerMedDRA version: 9.1Level: LLTClassification code 10026469Term: Malignant neoplasm of specified parts of peritoneumMedDRA version: 9.1Level: LLTClassification code 10026340Term: Malignant neoplasm of peritoneum, unspecifiedEUCTR2008-006831-10-ESBoehringer Ingelheim España, S.A.1,300
进行中（未招募）
不适用
Estudio de Fase III, multicéntrico, aleatorizado y abierto para evaluar la eficacia y la seguridad de nilotinib frente a imatinib, en pacientes adultos con tumores del estroma gastrointestinal (GIST) metastáticos o irresecables - N/AEUCTR2008-004758-34-ESovartis Farmacéutica S.A.736
进行中（未招募）
1 期
Estudio de fase III, aleatorizado, multicéntrico, doble ciego, deequivalencia terapéutica de un FEC-G biosimilar (filgrastim dePLIVA/Mayne) frente a Neupogen® (filgrastim de Amgen) en sujetos quereciben doxorubicina y docetaxel como terapia de combinación para elcáncer de mamaA Phase III randomised, multicentre, double-blind, therapeutic equivalence study of biosimilar G-CSF (PLIVA/Mayne filgrastim) versus Neupogen (filgrastim-Amgen) in subjects receiving doxorubicin and docetaxel as a combination chemotherapy regimen for breast cancer.Este estudio se diseña para demostrar la equivalencia terapéutica de filgrastrim de PLIVA /Mayne y Neupogen en la reducción de la duración de la neutropenia y en la incidencia de neutropenia febril en sujetos que reciben quimioterapia.This study is designed to demonstrate the therapeutic equivalence of PLIVA/Mayne filgrastim and Neupogen for the reduction in duration of neutropenia and the incidence of febrile neutropenia, in subjects receiving chemotherapy.MedDRA version: 9.1Level: LLTClassification code 10029354Term: NeutropeniaEUCTR2007-000394-36-ESMayne Pharma Plc279
进行中（未招募）
1 期
Estudio de fase III, multicéntrico, aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, para evaluar la eficacia y seguridad del agonista beta-3 YM178 (25 mg, una vez al día y 50 mg, una vez al día) en pacientes con síntomas de vejiga hiperactiva.A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist YM178 (25 mg qd and 50 mg qd) in Subjects with Symptoms of Overactive Bladder - CAPRICOREUCTR2008-007087-42-ESAstellas Pharma Europe B.V.1,300